ESTRO 2024 - Abstract Book

S2447

Clinical - Urology

ESTRO 2024

- [18-24[ months

24.8

18.8

9.4

1.4

15.2

- [24-36] months

55.1

42.2

24.0

12.6

37.0

- >36 months

0

0

0

1.0

0.3

- For life

4.3

12.5

28.1

66.7

25.9

Primary reason of choice of planned total duration* (%)

- Gleason score

- French (AFU) and/or international (EAU) guidelines

45.3

30.5

9.4

3.4

26.3

23.9

13.3

20.8

30.9

23.2

- PSA level

- Number of bone metastases

15.2

18.8

22.9

8.7

15.8

- cTN

0.3

0

2.1

39.1

10.7

- PSA doubling time

- Age

9.0

17.2

5.2

3.4

8.4

0.6

2.3

19.8

1.9

4.0

2.5

5.5

1.0

3.9

3.4

Concomitant PCa Tts* (%)

83.0

67.2

49.0

57.5

69.3

- External radiotherapy (RT) on prostate area

78.3

55.5

19.8

13.0

48.5

- 2-4 week anti-androgen Tt (to avoid flare-up)

- External nodal RT

34.1

29.7

25.0

26.1

30.5

-

New

generation

hormonal Tt

34.1

26.6

17.7

7.7

23.1